STAAR Surgical Company
STAAR Surgical Company
Your view on STAA
Overview
What the company does, where it operates, and who runs it.
About STAAR Surgical Company
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Stephen C. Farrell CFA
- Headquarters
- 25651 Atlantic Ocean Drive, Lake Forest, CA, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Stephen C. Farrell CFA
- Headquarters
- 25651 Atlantic Ocean Drive, Lake Forest, CA, US
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.
The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery.
In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.
STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for STAAR Surgical Company, and the rating behind it. STAA last traded at $22.26, 278.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for STAAR Surgical Company. Starting points for STAAR Surgical Company: P/E 278.9, EPS $0.08, beta 1.18 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for STAAR Surgical Company. STAAR Surgical Company does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for STAAR Surgical Company. Trailing twelve-month EPS for STAAR Surgical Company stands at $0.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for STAAR Surgical Company. STAAR Surgical Company has reported as a listed company since 1992. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
STAAR Surgical Company valued side by side against its closest peers. STAAR Surgical Company is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold STAAR Surgical Company, and how their positions are changing. At a $1.12B market value, institutional positions materially move STAAR Surgical Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by STAAR Surgical Company executives and directors. Shares of STAAR Surgical Company have traded between $13.50 and $30.81 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming STAAR Surgical Company. STAAR Surgical Company is a $1.12B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming STAAR Surgical Company. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for STAAR Surgical Company. Coverage tracks STAAR Surgical Company within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.